195 related articles for article (PubMed ID: 19880790)
1. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.
Midyett LK; Rogol AD; Van Meter QL; Frane J; Bright GM;
J Clin Endocrinol Metab; 2010 Feb; 95(2):611-9. PubMed ID: 19880790
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
Chernausek SD; Backeljauw PF; Frane J; Kuntze J; Underwood LE;
J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
[TBL] [Abstract][Full Text] [Related]
4. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children.
Cohen P; Germak J; Rogol AD; Weng W; Kappelgaard AM; Rosenfeld RG;
J Clin Endocrinol Metab; 2010 May; 95(5):2089-98. PubMed ID: 20207829
[TBL] [Abstract][Full Text] [Related]
5. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
[TBL] [Abstract][Full Text] [Related]
6. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
[TBL] [Abstract][Full Text] [Related]
7. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO
Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
[TBL] [Abstract][Full Text] [Related]
9. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research center study. GHIS Collaborative Group.
Backeljauw PF; Underwood LE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3312-7. PubMed ID: 8784089
[TBL] [Abstract][Full Text] [Related]
10. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study.
Cohen P; Rogol AD; Howard CP; Bright GM; Kappelgaard AM; Rosenfeld RG;
J Clin Endocrinol Metab; 2007 Jul; 92(7):2480-6. PubMed ID: 17356043
[TBL] [Abstract][Full Text] [Related]
11. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
[TBL] [Abstract][Full Text] [Related]
12. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human insulin-like growth factor-I therapy for children with growth disorders.
Richmond EJ; Rogol AD
Adv Ther; 2008 Dec; 25(12):1276-87. PubMed ID: 19066756
[TBL] [Abstract][Full Text] [Related]
14. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trial.
Blum WF; Crowe BJ; Quigley CA; Jung H; Cao D; Ross JL; Braun L; Rappold G;
J Clin Endocrinol Metab; 2007 Jan; 92(1):219-28. PubMed ID: 17047016
[TBL] [Abstract][Full Text] [Related]
16. Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation - first three years of Polish experience.
Petriczko E; Jackowski T; Horodnicka-Józwa A; Wikiera B; Noczyńska A; Korpal-Szczyrska M; Birkholz-Walerzak D; Małecka-Tendera E; Kalina-Fraska B; Kalina M; Barg E; Beń-Skowronek I; Szewczyk L; Hilczer M; Smyczyńska J; Stawerska R; Lewiński A; Ziora K; Bossowski A; Pietrewicz E; Pyrżak B; Kędzia A; Szalecki M; Kilian A; Walczak M
Endokrynol Pol; 2019; 70(1):20-27. PubMed ID: 30351442
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor-I response to growth hormone is increased in prepubertal children with obesity and tall stature.
Bouhours-Nouet N; Gatelais F; Boux de Casson F; Rouleau S; Coutant R
J Clin Endocrinol Metab; 2007 Feb; 92(2):629-35. PubMed ID: 17090643
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.
Guevara-Aguirre J; Vasconez O; Martinez V; Martinez AL; Rosenbloom AL; Diamond FB; Gargosky SE; Nonoshita L; Rosenfeld RG
J Clin Endocrinol Metab; 1995 Apr; 80(4):1393-8. PubMed ID: 7536209
[TBL] [Abstract][Full Text] [Related]
19. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F
J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
[TBL] [Abstract][Full Text] [Related]
20. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
